STADA agreement extended for the Nordic Region
Enzymatica and its German partner STADA have extended the agreement for the common cold spray ViruProtect® (ColdZyme) for the Nordic Region excluding Sweden. Thus, the extended agreement includes Denmark, Norway, Finland and Iceland. The launch of ViruProtect in these markets is expected to take place in 2021. The cough & cold market for Denmark, Norway, Finland and Iceland is estimated to almost SEK 1.5 billion[1].Since earlier Enzymatica and STADA have a successful co-operation for the sale of ViruProtect in a large number of countries, mainly in Europe but also in Russia, Poland, Ukraine